Literature DB >> 19116263

Clonidine pharmacokinetics in pregnancy.

M L Buchanan1, T R Easterling, D B Carr, D D Shen, L J Risler, W L Nelson, D R Mattison, M F Hebert.   

Abstract

The objective of this study was to determine the pharmacokinetic parameters of clonidine during pregnancy compared with previously published data in nonpregnant subjects. Serial blood and urine samples were collected in 17 women during mid to late pregnancy over one steady-state dosing interval to determine clonidine noncompartmental pharmacokinetic parameters (n = 17) and creatinine clearance. In six of these pregnant subjects, maternal and umbilical cord (venous and arterial) plasma samples were collected at the time of delivery for measurement of clonidine concentrations. Clonidine apparent oral clearance was found to be 440 +/- 168 ml/min during pregnancy compared with 245 +/- 72 ml/min as previously reported in nonpregnant subjects (p < 0.0001) (Cunningham et al., 1994). There was a strong correlation (r = 0.82, p < 0.001) between clonidine renal clearance, adjusted for variation in glomerular filtration rate, and urine pH. Umbilical cord to maternal plasma clonidine concentration ratios were 1.0 +/- 0.1 (arterial) and 1.0 +/- 0.1 (venous). In conclusion, clonidine is cleared more rapidly in pregnant women than in nonpregnant subjects. At the time of delivery, the fetus is exposed to similar plasma clonidine concentrations as the mother.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116263      PMCID: PMC2680537          DOI: 10.1124/dmd.108.024984

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

Review 1.  Central alpha-adrenergic systems as targets for hypotensive drugs.

Authors: 
Journal:  Rev Physiol Biochem Pharmacol       Date:  1978       Impact factor: 5.545

2.  Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.

Authors:  D S Davies; A M Wing; J L Reid; D M Neill; P Tippett; C T Dollery
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

3.  Clinical efficacy and pharmacokinetics of clonidine in hemodialysis and renal insufficiency.

Authors:  H N Hulter; J H Licht; L P Ilnicki; S Singh
Journal:  J Lab Clin Med       Date:  1979-08

Review 4.  Pharmacokinetics of clonidine.

Authors:  D T Lowenthal
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

5.  Serial changes in 24 hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy.

Authors:  J M Davison; M C Noble
Journal:  Br J Obstet Gynaecol       Date:  1981-01

6.  New aspects of the clinical pharmacology of clonidine.

Authors:  D Arndts
Journal:  Chest       Date:  1983-02       Impact factor: 9.410

7.  A newly developed precise and sensitive radioimmunoassay for clonidine.

Authors:  D Arndts; H Stähle; C J Struck
Journal:  Arzneimittelforschung       Date:  1979

8.  Pharmacokinetics of clonidine during pregnancy and nursing.

Authors:  A L Hartikainen-Sorri; J E Heikkinen; M Koivisto
Journal:  Obstet Gynecol       Date:  1987-04       Impact factor: 7.661

9.  Clonidine: placental transfer and neonatal adaption.

Authors:  M J Boutroy; C R Gisonna; M Legagneur
Journal:  Early Hum Dev       Date:  1988 Aug-Sep       Impact factor: 2.079

10.  Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.

Authors:  M F Hebert; T R Easterling; B Kirby; D B Carr; M L Buchanan; T Rutherford; K E Thummel; D P Fishbein; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2008-02-20       Impact factor: 6.903

View more
  25 in total

1.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

2.  Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth.

Authors:  Sophia Rothberger; Darcy Carr; Debra Brateng; Mary Hebert; Thomas R Easterling
Journal:  Am J Hypertens       Date:  2010-08-19       Impact factor: 2.689

3.  Pharmacokinetics of oseltamivir among pregnant and nonpregnant women.

Authors:  Richard H Beigi; Kelong Han; Raman Venkataramanan; Gary D Hankins; Shannon Clark; Mary F Hebert; Thomas Easterling; Anne Zajicek; Zhaoxia Ren; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2011-03-09       Impact factor: 8.661

Review 4.  Transcriptional Regulation of CYP2D6 Expression.

Authors:  Xian Pan; Miaoran Ning; Hyunyoung Jeong
Journal:  Drug Metab Dispos       Date:  2016-10-03       Impact factor: 3.922

5.  Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic.

Authors:  David M Haas; Sara K Quinney; Jayanti M Clay; Jamie L Renbarger; Mary F Hebert; Shannon Clark; Jason G Umans; Steve N Caritis
Journal:  Am J Perinatol       Date:  2012-08-08       Impact factor: 1.862

Review 6.  Pharmacological management of hypertension in pregnancy.

Authors:  Thomas R Easterling
Journal:  Semin Perinatol       Date:  2014-10-11       Impact factor: 3.300

7.  CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids.

Authors:  Muhammad Farooq; Edward J Kelly; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2016-03-10       Impact factor: 3.922

Review 8.  Pharmacogenetics and individualizing drug treatment during pregnancy.

Authors:  David M Haas
Journal:  Pharmacogenomics       Date:  2014-01       Impact factor: 2.533

9.  Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Authors:  Nina Isoherranen; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2013-02       Impact factor: 3.922

10.  Pharmacogenetics and other reasons why drugs can fail in pregnancy: higher dose or different drug?

Authors:  David M Haas; Mary DʼAlton
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.